1. Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S‐1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi‐Institutional Dataset Analysis
   Akimitsu Iizuka et al, 2019, World Journal of Surgery CrossRef
2. Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001)
   Takeshi Kawakami et al, 2022, Gastric Cancer CrossRef
3. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial
   Shigeru Tatebe et al, 2014, Gastric Cancer CrossRef
4. Total gastrectomy increases the incidence of grade III and IV toxicities in patients with gastric cancer receiving adjuvant TS-1 treatment
   Wen-Chi Chou et al, 2013, World Journal of Surgical Oncology CrossRef
5. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study
   Kotaro Yamashita et al, 2017, Annals of Surgical Oncology CrossRef
6. Impact of postoperative infectious complications on adjuvant chemotherapy administration after gastrectomy for advanced gastric cancer
   Hironori Tsujimoto et al, 2021, Japanese Journal of Clinical Oncology CrossRef
7. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists
   Yosuke Kano et al, 2020, Surgery Today CrossRef
8. Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer
   Koichi Ogawa et al, 2020, International Journal of Clinical Oncology CrossRef
9. Questionnaire survey on adjuvant chemotherapy for elderly patients after gastrectomy indicates their vulnelabilities
   Toshiyuki Tanahashi et al, 2019, Gastric Cancer CrossRef